Dr. Chandarlapaty received a BS in Chemistry from the College of William and Mary followed by a PhD in Biochemistry in 1998 at the University of North Carolina. For his doctoral dissertation, he worked under Professor Beverly Errede on the role of the ASH1 transcription factor in regulating pseudohyphal differentiation in Saccharomyces cerevisiae. He then obtained his MD in 2002 at the Wake Forest School of Medicine. He furthered his clinical training with a Residency in Internal Medicine at New York Presbyterian Hospital and Fellowship in Medical Oncology at Memorial Sloan Kettering Cancer Center (MSKCC). During fellowship, Dr. Chandarlapaty conducted postdoctoral research in the laboratory of Professor Neal Rosen, studying regulation of PI3K/AKT signaling in breast cancer. There he led research on how cancer cells have activated feedback regulation of oncogenic networks that ultimately play a role in adaptive drug resistance. In 2012, Dr. Chandarlapaty joined the faculty of the Human Oncology and Pathogenesis Program at MSKCC as a Laboratory Head and Attending Physician. Over the last 5 years, Dr. Chandarlapaty’s laboratory has had a particular focus on understanding the basis for resistance to endocrine therapies in breast cancer. His laboratory helped identify and characterize mutation in ESR1 as the dominant mechanism of clinical resistance to aromatase inhibitors. Following on the heels of this work, he has helped lead the development of ER antagonists as a means of overcoming ER mutants. The laboratory’s ongoing work is to understand the molecular basis for hormone and growth factor regulation of breast cancer progression and drug resistance.